Strategies to tackle RAS-mutated metastatic colorectal cancer

The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal growth factor receptor (EGFR) antibodies. In the last decades, se...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:ESMO Open
Autors principals: Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D.A., Pani, A., Scaglione, F., Siena, S., Sartore-Bianchi, A.
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8167159/
https://ncbi.nlm.nih.gov/pubmed/34044286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.esmoop.2021.100156
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars